Fludarabine alone compared to CHVP plus interferon in elderly patients with follicular lymphoma and adverse prognostic parameters: A GELA study
Identifieur interne : 001A29 ( Main/Exploration ); précédent : 001A28; suivant : 001A30Fludarabine alone compared to CHVP plus interferon in elderly patients with follicular lymphoma and adverse prognostic parameters: A GELA study
Auteurs : B. Coiffier [France] ; E. M. Neidhardt-Bérard [France] ; H. Tilly ; C. Belanger [France] ; R. Bouabdallah [France] ; C. Haioun ; P. Brice [France] ; P. Y. Péaud ; J. L. Pico ; M. Janvier ; P. Solal-Celigny [France] ; N. Brousse [France]Source :
- Annals of Oncology [ 0923-7534 ] ; 1999-10.
Abstract
Background: Fludarabine was associated with a good response and was well tolerated in patients with follicular lymphoma in phase II trials and this treatment may be associated with less adverse events than treatment with CHVP plus interferon in elderly patients. Patients and methods: One hundred thirty-one patients older than 59 years with a follicular lymphoma and poor prognosis were randomized between the association of CHVP (12 cycles in 18 months) plus interferon (5 MU TIW for 18 months) or fludarabine alone (25 mg/m2/d × 5 days for 6 cycles, then 20 mg/m2/day for 6 further cycles for 18 months). Poor prognosis was defined by the presence of a large tumor mass, poor performance status, the presence of B symptoms, above normal LDH level, or ≥ 3 mg/1 β-microglobulin level. Results: Patients treated with CHVP plus interferon had a higher response to treatment, a longer time to progression and a longer survival than those treated with fludarabine alone (P < 0.05 for all analyses). With a median follow-up of 29 months, the 2-year failure-free survival was 63% for the CHVP-plus-interferon arm compared to 49% for the fludarabine arm and the two-year survival was 77% and 62%, respectively. This benefit was confirmed in a multivariate analysis including initial prognostic parameters. Fludarabine alone was associated with less neutropenia than CHVP plus interferon. Interferon was decreased or stopped in 39% of the patients because of severe fatigue. Conclusions: CHVP plus interferon over 18 months was associated with a better outcome, even though the combination of interferon plus chemotherapy was less well tolerated than fludarabine.
Url:
DOI: 10.1023/A:1008347425795
Affiliations:
- France
- Auvergne-Rhône-Alpes, Provence-Alpes-Côte d'Azur, Rhône-Alpes, Île-de-France
- Lyon, Marseille, Paris
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001457
- to stream Istex, to step Curation: 001457
- to stream Istex, to step Checkpoint: 000A38
- to stream Main, to step Merge: 001A78
- to stream Main, to step Curation: 001A29
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Fludarabine alone compared to CHVP plus interferon in elderly patients with follicular lymphoma and adverse prognostic parameters: A GELA study</title><author><name sortKey="Coiffier, B" sort="Coiffier, B" uniqKey="Coiffier B" first="B." last="Coiffier">B. Coiffier</name></author><author><name sortKey="Neidhardt Berard, E M" sort="Neidhardt Berard, E M" uniqKey="Neidhardt Berard E" first="E. M." last="Neidhardt-Bérard">E. M. Neidhardt-Bérard</name></author><author><name sortKey="Tilly, H" sort="Tilly, H" uniqKey="Tilly H" first="H." last="Tilly">H. Tilly</name></author><author><name sortKey="Belanger, C" sort="Belanger, C" uniqKey="Belanger C" first="C." last="Belanger">C. Belanger</name></author><author><name sortKey="Bouabdallah, R" sort="Bouabdallah, R" uniqKey="Bouabdallah R" first="R." last="Bouabdallah">R. Bouabdallah</name></author><author><name sortKey="Haioun, C" sort="Haioun, C" uniqKey="Haioun C" first="C." last="Haioun">C. Haioun</name></author><author><name sortKey="Brice, P" sort="Brice, P" uniqKey="Brice P" first="P." last="Brice">P. Brice</name></author><author><name sortKey="Peaud, P Y" sort="Peaud, P Y" uniqKey="Peaud P" first="P. Y." last="Péaud">P. Y. Péaud</name></author><author><name sortKey="Pico, J L" sort="Pico, J L" uniqKey="Pico J" first="J. L." last="Pico">J. L. Pico</name></author><author><name sortKey="Janvier, M" sort="Janvier, M" uniqKey="Janvier M" first="M." last="Janvier">M. Janvier</name></author><author><name sortKey="Solal Celigny, P" sort="Solal Celigny, P" uniqKey="Solal Celigny P" first="P." last="Solal-Celigny">P. Solal-Celigny</name></author><author><name sortKey="Brousse, N" sort="Brousse, N" uniqKey="Brousse N" first="N." last="Brousse">N. Brousse</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:76963C2957897CF443D888070F05980578B00155</idno><date when="1999" year="1999">1999</date><idno type="doi">10.1023/A:1008347425795</idno><idno type="url">https://api.istex.fr/document/76963C2957897CF443D888070F05980578B00155/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001457</idno><idno type="wicri:Area/Istex/Curation">001457</idno><idno type="wicri:Area/Istex/Checkpoint">000A38</idno><idno type="wicri:doubleKey">0923-7534:1999:Coiffier B:fludarabine:alone:compared</idno><idno type="wicri:Area/Main/Merge">001A78</idno><idno type="wicri:Area/Main/Curation">001A29</idno><idno type="wicri:Area/Main/Exploration">001A29</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Fludarabine alone compared to CHVP plus interferon in elderly patients with follicular lymphoma and adverse prognostic parameters: A GELA study</title><author><name sortKey="Coiffier, B" sort="Coiffier, B" uniqKey="Coiffier B" first="B." last="Coiffier">B. Coiffier</name><affiliation wicri:level="3"><country>France</country><placeName><settlement type="city">Lyon</settlement><region type="region" nuts="2">Auvergne-Rhône-Alpes</region><region type="old region" nuts="2">Rhône-Alpes</region></placeName><wicri:orgArea>Groupe d Etudes des Lymphomes de VAdulte (GELA)</wicri:orgArea></affiliation><affiliation wicri:level="1"><country wicri:rule="url">France</country></affiliation></author><author><name sortKey="Neidhardt Berard, E M" sort="Neidhardt Berard, E M" uniqKey="Neidhardt Berard E" first="E. M." last="Neidhardt-Bérard">E. M. Neidhardt-Bérard</name><affiliation wicri:level="3"><country>France</country><placeName><settlement type="city">Lyon</settlement><region type="region" nuts="2">Auvergne-Rhône-Alpes</region><region type="old region" nuts="2">Rhône-Alpes</region></placeName><wicri:orgArea>Groupe d Etudes des Lymphomes de VAdulte (GELA)</wicri:orgArea></affiliation></author><author><name sortKey="Tilly, H" sort="Tilly, H" uniqKey="Tilly H" first="H." last="Tilly">H. Tilly</name><affiliation><wicri:noCountry code="subField">Rouen</wicri:noCountry></affiliation></author><author><name sortKey="Belanger, C" sort="Belanger, C" uniqKey="Belanger C" first="C." last="Belanger">C. Belanger</name><affiliation wicri:level="3"><country>France</country><placeName><settlement type="city">Paris</settlement><region type="région" nuts="2">Île-de-France</region></placeName><wicri:orgArea>Groupe d Etudes des Lymphomes de VAdulte (GELA)</wicri:orgArea></affiliation></author><author><name sortKey="Bouabdallah, R" sort="Bouabdallah, R" uniqKey="Bouabdallah R" first="R." last="Bouabdallah">R. Bouabdallah</name><affiliation wicri:level="3"><country>France</country><placeName><settlement type="city">Marseille</settlement><region type="région" nuts="2">Provence-Alpes-Côte d'Azur</region></placeName><wicri:orgArea>Groupe d Etudes des Lymphomes de VAdulte (GELA)</wicri:orgArea></affiliation></author><author><name sortKey="Haioun, C" sort="Haioun, C" uniqKey="Haioun C" first="C." last="Haioun">C. Haioun</name><affiliation><wicri:noCountry code="subField">Creteil</wicri:noCountry></affiliation></author><author><name sortKey="Brice, P" sort="Brice, P" uniqKey="Brice P" first="P." last="Brice">P. Brice</name><affiliation wicri:level="3"><country>France</country><placeName><settlement type="city">Paris</settlement><region type="région" nuts="2">Île-de-France</region></placeName><wicri:orgArea>Groupe d Etudes des Lymphomes de VAdulte (GELA)</wicri:orgArea></affiliation></author><author><name sortKey="Peaud, P Y" sort="Peaud, P Y" uniqKey="Peaud P" first="P. Y." last="Péaud">P. Y. Péaud</name><affiliation><wicri:noCountry code="subField">Valence</wicri:noCountry></affiliation></author><author><name sortKey="Pico, J L" sort="Pico, J L" uniqKey="Pico J" first="J. L." last="Pico">J. L. Pico</name><affiliation><wicri:noCountry code="subField">Villejuif</wicri:noCountry></affiliation></author><author><name sortKey="Janvier, M" sort="Janvier, M" uniqKey="Janvier M" first="M." last="Janvier">M. Janvier</name><affiliation><wicri:noCountry code="subField">Saint-Cloud</wicri:noCountry></affiliation></author><author><name sortKey="Solal Celigny, P" sort="Solal Celigny, P" uniqKey="Solal Celigny P" first="P." last="Solal-Celigny">P. Solal-Celigny</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Groupe d Etudes des Lymphomes de VAdulte (GELA), Clinique Victor Hugo Le Mans</wicri:regionArea><wicri:noRegion>Clinique Victor Hugo Le Mans</wicri:noRegion><wicri:noRegion>Clinique Victor Hugo Le Mans</wicri:noRegion></affiliation></author><author><name sortKey="Brousse, N" sort="Brousse, N" uniqKey="Brousse N" first="N." last="Brousse">N. Brousse</name><affiliation wicri:level="3"><country>France</country><placeName><settlement type="city">Paris</settlement><region type="région" nuts="2">Île-de-France</region></placeName><wicri:orgArea>Groupe d Etudes des Lymphomes de VAdulte (GELA)</wicri:orgArea></affiliation></author></analytic><monogr></monogr><series><title level="j">Annals of Oncology</title><idno type="ISSN">0923-7534</idno><idno type="eISSN">1569-8041</idno><imprint><publisher>Oxford University Press</publisher><date type="published" when="1999-10">1999-10</date><biblScope unit="volume">10</biblScope><biblScope unit="issue">10</biblScope><biblScope unit="page" from="1191">1191</biblScope><biblScope unit="page" to="1197">1197</biblScope></imprint><idno type="ISSN">0923-7534</idno></series><idno type="istex">76963C2957897CF443D888070F05980578B00155</idno><idno type="DOI">10.1023/A:1008347425795</idno><idno type="ArticleID">10.10.1191</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0923-7534</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract">Background: Fludarabine was associated with a good response and was well tolerated in patients with follicular lymphoma in phase II trials and this treatment may be associated with less adverse events than treatment with CHVP plus interferon in elderly patients. Patients and methods: One hundred thirty-one patients older than 59 years with a follicular lymphoma and poor prognosis were randomized between the association of CHVP (12 cycles in 18 months) plus interferon (5 MU TIW for 18 months) or fludarabine alone (25 mg/m2/d × 5 days for 6 cycles, then 20 mg/m2/day for 6 further cycles for 18 months). Poor prognosis was defined by the presence of a large tumor mass, poor performance status, the presence of B symptoms, above normal LDH level, or ≥ 3 mg/1 β-microglobulin level. Results: Patients treated with CHVP plus interferon had a higher response to treatment, a longer time to progression and a longer survival than those treated with fludarabine alone (P < 0.05 for all analyses). With a median follow-up of 29 months, the 2-year failure-free survival was 63% for the CHVP-plus-interferon arm compared to 49% for the fludarabine arm and the two-year survival was 77% and 62%, respectively. This benefit was confirmed in a multivariate analysis including initial prognostic parameters. Fludarabine alone was associated with less neutropenia than CHVP plus interferon. Interferon was decreased or stopped in 39% of the patients because of severe fatigue. Conclusions: CHVP plus interferon over 18 months was associated with a better outcome, even though the combination of interferon plus chemotherapy was less well tolerated than fludarabine.</div></front></TEI><affiliations><list><country><li>France</li></country><region><li>Auvergne-Rhône-Alpes</li><li>Provence-Alpes-Côte d'Azur</li><li>Rhône-Alpes</li><li>Île-de-France</li></region><settlement><li>Lyon</li><li>Marseille</li><li>Paris</li></settlement></list><tree><noCountry><name sortKey="Haioun, C" sort="Haioun, C" uniqKey="Haioun C" first="C." last="Haioun">C. Haioun</name><name sortKey="Janvier, M" sort="Janvier, M" uniqKey="Janvier M" first="M." last="Janvier">M. Janvier</name><name sortKey="Peaud, P Y" sort="Peaud, P Y" uniqKey="Peaud P" first="P. Y." last="Péaud">P. Y. Péaud</name><name sortKey="Pico, J L" sort="Pico, J L" uniqKey="Pico J" first="J. L." last="Pico">J. L. Pico</name><name sortKey="Tilly, H" sort="Tilly, H" uniqKey="Tilly H" first="H." last="Tilly">H. Tilly</name></noCountry><country name="France"><region name="Auvergne-Rhône-Alpes"><name sortKey="Coiffier, B" sort="Coiffier, B" uniqKey="Coiffier B" first="B." last="Coiffier">B. Coiffier</name></region><name sortKey="Belanger, C" sort="Belanger, C" uniqKey="Belanger C" first="C." last="Belanger">C. Belanger</name><name sortKey="Bouabdallah, R" sort="Bouabdallah, R" uniqKey="Bouabdallah R" first="R." last="Bouabdallah">R. Bouabdallah</name><name sortKey="Brice, P" sort="Brice, P" uniqKey="Brice P" first="P." last="Brice">P. Brice</name><name sortKey="Brousse, N" sort="Brousse, N" uniqKey="Brousse N" first="N." last="Brousse">N. Brousse</name><name sortKey="Coiffier, B" sort="Coiffier, B" uniqKey="Coiffier B" first="B." last="Coiffier">B. Coiffier</name><name sortKey="Neidhardt Berard, E M" sort="Neidhardt Berard, E M" uniqKey="Neidhardt Berard E" first="E. M." last="Neidhardt-Bérard">E. M. Neidhardt-Bérard</name><name sortKey="Solal Celigny, P" sort="Solal Celigny, P" uniqKey="Solal Celigny P" first="P." last="Solal-Celigny">P. Solal-Celigny</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/France/explor/LeHavreV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001A29 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001A29 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/France
|area= LeHavreV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:76963C2957897CF443D888070F05980578B00155
|texte= Fludarabine alone compared to CHVP plus interferon in elderly patients with follicular lymphoma and adverse prognostic parameters: A GELA study
}}
| This area was generated with Dilib version V0.6.25. |  |